WHO Issues First Guidelines on Child Obesity

The World Health Organization (WHO) has released its first-ever clinical guidelines on managing pediatric and adolescent obesity.
The guidelines set age-differentiated protocols: no weight-loss pharmacotherapy or bariatric surgery for children under nine; restricted conditional medical interventions for adolescents aged 10–19.

Strongly advise against anti-obesity drugs, including GLP-1 receptor agonists such as semaglutide.
Strongly advise against bariatric surgeries such as gastric bypass.
Standard of care: family-centered behavioral modifications, structured nutrition, and physical activity.

Approved anti-obesity medicines may be considered only when a supervised multimodal lifestyle programme fails to achieve the desired results.
Bariatric surgery may be considered under strict conditions for adolescents with severe obesity.

WHO noted an absence of long-term clinical trial data on pediatric safety, efficacy, treatment duration, and tapering protocols of anti-obesity drugs like semaglutide.
Medical consensus in India cautions that pediatric bariatric surgery carries severe risks of micronutrient malabsorption and impaired physiological growth.

Obesity management should address psychological challenges including anxiety, depression, low self-esteem, stigma, and bullying.
Care should be family-engaged and age-appropriate.
WHO conditionally recommends digital health interventions: active video games (exergames), pedometers, accelerometers, and fitness applications.
Aim: replace sedentary screen time with active movement.

As of 2024, 170 million children and adolescents aged 5–19 live with obesity globally.
70 million children aged 5–9.
100 million adolescents aged 10–19.
The fastest acceleration is occurring in Low- and Middle-Income Countries (LMICs).

A Lancet study shows obese boys in India surged from 0.2 million in 1990 to 7.3 million in 2022.
Obese girls increased from 0.2 million to 5.2 million.
The Comprehensive National Nutrition Survey (CNNS) projects India will house over 27 million obese youth aged 5–19, accounting for 11% of the global burden.
This compounds India's dual burden of malnutrition — undernutrition and obesity coexisting.

The Central Drugs Standard Control Organisation (CDSCO) has approved semaglutide for adolescents aged 12 and above, strictly for morbid obesity with comorbidities such as non-alcoholic fatty liver disease (NAFLD) and prediabetes.
Medical consensus warns against pediatric bariatric surgery due to micronutrient malabsorption and impaired physiological growth.

Article 47, DPSP: The State shall raise the level of nutrition, standard of living, improve public health, and prohibit substances injurious to health.
National Health Policy 2017: Targets reduction in premature mortality from NCDs and promotes healthy lifestyles.
Food Safety and Standards Act, 2006: FSSAI regulates food labeling; front-of-pack warning labels for high fat, sugar, and salt foods are debated.
Drugs and Cosmetics Act, 1940: CDSCO regulates approval of drugs such as semaglutide.
POSHAN Abhiyaan / Mission Saksham Anganwadi and Poshan 2.0: Focuses on maternal and child nutrition; needs explicit obesity prevention.
National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD): Addresses obesity, diabetes, and cardiovascular diseases.
Ayushman Bharat Health and Wellness Centres: Provide NCD screening and lifestyle counseling.

Highlights WHO's normative role in global health standard-setting.
Raises policy questions on regulating pediatric pharmacotherapy, marketing of ultra-processed foods, and digital health.
India faces a dual malnutrition burden and needs integrated nutrition, mental health, and NCD strategies.
Useful for GS2 health governance, GS3 science and technology, and essays on public health.